Biotech firm Synedgen has been awarded a $1.96 million phase II Small Business Innovation Research grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen's proprietary oral disease treatments.
Under this two-year effort, which begins April 1, Synedgen will accelerate the development of Regenasyn, a topical treatment for oral mucositis that both prevents infection and improves healing, the company said.
"Severe oral mucositis is the leading reason cancer patients stop or delay treatment," stated Shenda Baker, PhD, Synedgen president, in a press release. "While there are very limited therapies to reduce the symptoms of mucositis in some chemotherapy and immunosuppressed patients, no current treatment provides successful improvement in radiation-induced mucositis."
Laboratory and animal research with Synedgen's products have so far demonstrated anti-inflammatory and tissue regenerative properties in injured and damaged tissues, the company said.
